SUMMARY Adrenergic responsiveness after abrupt propranolol withdrawal during exogenous and endogenous catecholamine stimulation was assessed in 10 normal subjects and 10 patients with angina pectoris. Propranolol, 160 mg/day, was administered for 2 weeks and then stopped. During an epinephrine infusion, heart rate and systolic pressure-heart rate product were significantly reduced from control in the propranolol period (p < 0.005). There were no differences from control 96 hours after the drug had been stopped in both groups or at 144 hours in the angina patients who were studied for a longer time. At 48 hours of withdrawal, heart rate and the pressure-rate product were significantly less than control level in the angina patients, but not in the normal subjects. Similar results were observed during exercise in both groups. The epinephrine-induced increase in free fatty acids was blocked by propranolol (p < 0.005), was still attenuated at 48 hours of withdrawal (p < 0.05), but returned to control levels thereafter in both groups. Resting serum triiodothyronine levels decreased with propranolol (p < 0.005) and remained low throughout the withdrawal period. Measurements of dopamine ,B-hydroxylase, plasma platelet factor 4, and platelet aggregation at rest and after exercise did not change significantly during or after propranolol administration. Plasma norepinephrine and epinephrine values were not changed from control during the withdrawal period at rest or after exercise. We conclude that there is no evidence of hypersensitivity to ,-adrenergically mediated responses after abrupt propranolol withdrawal.
INCREASED SEVERITY of angina pectoris, ventricular arrhythmias, myocardial infarction and sudden death have been reported in patients with ischemic heart disease who are abruptly withdrawn from chronic oral propranolol therapy.'-5 Little information exists concerning the mechanism of these propranolol withdrawal phenomena, although the possibility of sympathetic hypersensitivity in the days after drug cessation has received the most interest. 6 Other explanations include progression of underlying coronary artery disease,5 enhanced platelet aggregation,7 increased triiodothyronine levels,8 alterations in plasma renin activity,9 or continued high levels of physical activity despite withdrawal of propranolol. The purpose of this study was to assess possible mechanisms for propranolol withdrawal phenomena by serial hemodynamic, hematologic, metabolic and endocrine measurements at rest and with both exogenous and endogenous catecholamine stimulation in normal subjects and in patients with angina pectoris.
The study population consisted of 20 subjects -10 normal volunteers, ages 22-30 years, and 10 patients with angina pectoris, ages 42-66 years. The normal subjects were studied first to assess the feasibility of the protocol and to determine the magnitude of any sympathetic hypersensitivity or other reactions. The results in the normal subjects suggested that we could study selected patients with angina pectoris. Nine of the 10 patients with angina had either a previous welldocumented myocardial infarction (seven patients) or angiographically proved stenosis of at least 70% of one or more coronary arteries (six patients). The remaining patient had typical angina during treadmill exercise with > 0.1 mV of horizontal ST-segment depression for > 0.08 second. All the patients had stable angina pectoris of at least 5 months duration occurring with a frequency ranging from one episode per week to three episodes per day (mean 6.5 episodes/week). Patients with severe hypertension, congestive heart failure, cerebrovascular disease, asthma or insulin-dependent diabetes mellitus were excluded. Informed consent was obtained from all subjects on a form approved by the University of Texas Health Science Center at San Antonio, Institutional Review Board.
Study Days
The same series of studies was performed on five days in the normal subjects and on six days in the angina patients. Two days, at least 48 hours apart, were used for control studies. Each subject was then given propranolol 40 mg four times per day for 12-16 704 days (mean 14 days) and studies were performed on one of the last 2 days of propranolol therapy, 2-3 hours after the last dose of propranolol. Propranolol was then abruptly stopped and the same studies were performed 48 and 96 hours after the first missed dose in the normal subjects, and additionally at 144 hours in the angina patients. Normal subjects were not hospitalized, but the angina patients were all hospitalized during the withdrawal phase of the study in the Special Diagnosis and Treatment Unit of the Veterans Administration Hospital.
Study Protocol
All studies were performed in the fasting state, supine, in a room containing resuscitation equipment. Each study was begun by inserting a 19-gauge scalp vein needle in a forearm vein and drawing 33 ml of blood for baseline hematologic studies. The needle was then connected to an i.v. line which was periodically flushed with normal saline in an amount approximately equivalent to the amount of blood removed. The subjects were allowed to rest quietly for 30 minutes. At that time, 24 A two-way analysis of variance was used to compare pre-and postexercise values of PF4, platelet aggregation and DOH. PF4 and platelet aggregation were analyzed after conversion to natural logarithms.22 All remaining statistical analyses were performed using a one-way analysis of variance for repeated measures and Dunnet's test was used to identify individual differences.
Results
Heart Rate Figure 1 represents the average heart rate at baseline, at 5 minutes of epinephrine infusion and with exercise in the normal subjects and in the angina patients for each study day. Heart rate is shown at 12 minutes of supine bicycle exercise in the normal subjects and at end-exercise in the angina patients. At rest, propranolol reduced resting heart rate in the normal subjects and in the angina patients (p < 0.005), and it remained less than control at 48 hours after withdrawal of propranolol in the angina patients (p < 0.05). Resting heart rate was unchanged during all other withdrawal periods compared with control. In both groups, the epinephrine-induced rise in heart rate was prevented by propranolol administration (p < 0.005) and remained reduced at 48 hours after withdrawal in the angina patients (p < 0.005). However, neither group showed an increase in the epinephrine-stimulated heart rate when control days were compared with the withdrawal period. During propranolol administration, the heart rate response to exercise was significantly decreased in both groups compared with control (p < 0.005), but was not different when comparing control with withdrawal values. Only three subjects had a heart rate rise 10% above control during withdrawal. Therefore, we could detect no consistent increases in heart rate at rest, with epinephrine or with exercise in any of the withdrawal periods compared with control. In fact, in the angina patients, baseline and epinephrine-stimulated heart rate remained depressed at 48 hours after propranolol 705 withdrawal. Figure 2 shows average systolic blood pressure at baseline, with epinephrine stimulation and with exercise. At rest, systolic blood pressure did not change significantly during these three phases at any time period. With epinephrine infusion systolic blood pressure rose consistently on propranolol in both groups (p < 0.005), but there was no difference between the control and withdrawal measurements. Propranolol significantly blunted the systolic blood pressure rise with exercise in both groups (p < 0.005), but control and withdrawal values were not different from each other. In only two instances was there more than a 10% increase in withdrawal values as compared to control. Thus, consistently exaggerated systolic blood pressure responses after abrupt propranolol withdrawal did not occur at rest, with epinephrine infusion, or with exercise.
Systolic Blood Pressure-Heart Rate Product Figure 3 illustrates the average systolic blood pressure-heart rate products. Propranolol reduced systolic blood pressure-heart rate product at baseline, during epinephrine and exercise in both groups, but withdrawal values again showed no differences from control except at 48 hours, when the products at baseline and during epinephrine were still depressed in the angina patients. Free Fatty Acids Figure 4 demonstrates the baseline and the peak FFA response to epinephrine infusion in both the normal subjects and in the angina patients. In all normal subjects and angina patients, the peak FFA response occurred 12-16 minutes after the onset of the epinephrine infusion. Propranolol did not change baseline FFA levels in either group and there were no differences in baseline control and withdrawal values. In response to the epinephrine infusion, propranolol blocked the rise in FFAs in both the normal and the angina patients (p < 0.005). However, FFA did not rise higher during the withdrawal period than during the control period in either group. In fact, the FFA rise in response to epinephrine was decreased at 48 hours of withdrawal compared with control (p < 0.05) in both groups. Thus, the epinephrine-stimulated FFA rise, although effectively blocked by propranolol, was not exaggerated after abrupt propranolol withdrawal.
Left Ventricular Performance and End-diastolic Dimension 
Propranolol Levels
Serum propranolol levels after 12-16 days (mean 14 days) of oral propranolol drawn 2-3 hours after the last dose averaged 71.3 ± 10 (± SD) ng/ml in the normals (range 23-155 ng/ml) and 55.9 ± 19.9 ng/ml in the angina patients (range 27-102 ng/ml) (NS). Propranolol levels drawn at 48, 96 and 144 hours after withdrawal were unmeasurable in all cases.
Catecholamines
In the angina patients, average control values for norepinephrine were 156 + 69 pg/ml at rest and 1123 ± 494 pg/ml after exercise. Control epinephrine values at rest were 18 ± 16 pg/ml at rest and 59 ± 33 Platelet Factor 4 Table 3 demonstrates the geometric means and 95% confidence limits for plasma PF4 concentrations at baseline, after epinephrine infusion and after exercise in both groups of patients. All epinephrine and exercise values are significantly increased over control (p < 0.001), but are not further modified by either propranolol administration or withdrawal. values did not change during exercise. In both groups 1 with exercise in normean aggregation data did not change on propranolol or during the withdrawal period compared with control at rest and after exercise.
Triiodothyronine Levels
Baseline total serum triiodothyronine was measured in each phase of this study (table 4) . Control values in normal subjects and in angina patients were equivalent. In both groups, propranolol significantly reduced total serum triiodothyronine (p < 0.05), and this reduction persisted throughout the entire withdrawal period.
Patient Responses
Most of the angina patients noted symptomatic improvement during propranolol therapy and their mean pg/ml after exercise. There were no significant changes in any of the withdrawal periods as compared to control in norepinephrine or epinephrine either at rest or after exercise.
Dopamine -}-Hydroxylase
In the angina patients, resting mean DO3H levels were unchanged throughout the study and all DOH levels drawn after exercise were slightly but significantly increased over resting values (p < 0.05).
This increase in DOH with exercise was identical in all phases of the study (table 2). Glaubiger and Lefkowitz2" showing that the number of cardiac /-adrenergic receptors increased in rats treated with propranolol for 2 weeks. However, even if this increase in cardiac /-adrenergic receptors reported in propranolol-treated rats reflects the response in patients with coronary artery disease, this need not imply an augmented physiologic response. Therefore, we measured multiple physiologic responses to /3-adrenergic stimulation before, during and after a course of propranolol.
Our results demonstrate that the abrupt withdrawal of propranolol after chronic oral administration in both normal subjects and patients with angina pectoris does not result in an exaggerated response of various hemodynamic, metabolic, hematologic and endocrine measures at rest or with high levels of stimulation by exogenous or endogenous catecholamines. The withdrawal study days encompass the time period in which most cases of propranolol withdrawal phenomoccurred 2 weeks or more after abrupt propranolol withdrawal, most were preceded by increasing angina beginning in the first 48 hours after withdrawal.3-5 In reports that contain detailed information,", " ' 5 22 of 23 patients had either increasing symptoms or an acute event in the first 6 days after withdrawal of propranolol.
Two studies with different conclusions from ours purport to have demonstrated hypersensitivity to isoproterenol infusions within the first 6 days after withdrawal.'6' 27 In the study of Boudoulas et al. of normal subjects,'6 increases in pulse pressure and heart rate over baseline were observed at 24-48 hours. We have shown that at 48 hours after stopping propranolol there is still substantial 03-adrenergic blockade of receptors modulating cardiac and metabolic activity. Other investigators also have found that blockade by propranolol lasts 48 hours or more after the last dose of the drug.27-29 The 2-day course of propranolol in the study by Boudoulas and co-workers may have been too short to produce this effect. The study by Nattel et al.'7 dealt with hypertensive patients without symptomatic coronary artery disease. The possibility that altered baroreceptor responses or other pathophysiologic alterations unique to the hypertensive state may have been responsible for their findings must be considered. Our study of patients with angina and coronary artery disease using 2 weeks of propranolol therapy is likely to be more relevant to the usual situation in which propranolol withdrawal phenomena occur than are the studies of Boudoulas et al. 26 and Nattel et al.27 In evaluating the possibility of hypersensitivity after propranolol withdrawal, we chose a wide range of physiologic measurements known to be under sympathetic control. The epinephrine-stimulated rise in FFAs is a well-known d-receptor-mediated response that has been studied by various investigators.30-"3 Although /-adrenergic blockade with propranolol was clearly demonstrated, we found no increase in FFA mobilization in the withdrawal period to suggest /-receptor hypersensitivity. Similar results were obtained in a recent study in dogs.34 With the combined a and A stimulation of epinephrine, we saw no exaggerated heart rate response in either our normal subjects or angina patients. Although the dose of epinephrine was purposely low to avoid precipitation of angina pectoris, it was enough to cause reproducible and significant hemodynamic effects. The reflex response to the a-vasoconstrictor properties of epinephrine could mask some of the expected heart rate increase; however, even heart rate-systolic blood pressure products showed no exaggerated changes in the withdrawal period compared with control. In addition, exercise to a symptom-limited maximum failed to provoke any rebound increase in heart rate or systolic blood pressure. Furthermore Propranolol is known to suppress total serum T3 levels in normal and hyperthyroid subjects. 37 38 Increases in free T3 over control have been reported to occur after withdrawal of propranolol in a few patients with hypertension.8 Total T3 did not increase after propranolol withdrawal in our normal subjects and angina patients, but we cannot exclude the possibility that free T3 increased. However, in one previous study,8 free and total T3 were closely related and changed in a parallel fashion. Accordingly, we believe that thyroid activity is not increased during the period when propranolol withdrawal phenomena occur and that the effect of 3-adrenergic blockade on thyroid function is considerably more sustained than the effect on the other parameters we measured.
Finally, there has been considerable interest in the role of platelets in atherosclerotic cardiovascular disease. Platelet aggregation may be enhanced in some patients with coronary artery disease.39 In one study, this enhanced platelet aggregation returned toward normal with propranolol therapy but showed a rebound increase after the sudden withdrawal of propranolol.7 Platelet aggregation was not significantly enhanced in our angina patients compared with the normal subjects. We found no decrease in aggregation thresholds in response to ADP with propranolol. This was true for both normal subjects and angina patients when assessed both at rest and after exercise. Platelet counts were unchanged in all phases of the study. Furthermore, PF4 showed no change when comparing control, propranolol, and withdrawal phases, again at baseline, after epinephrine infusion and after exercise. Since PF4 is an in vivo technique for assessing platelet secretion, these data complement the in vitro lack of changes seen in platelet aggregation. Therefore, we found no evidence to implicate abnormalities in platelet aggregation or secretion in the propranolol withdrawal phenomena.
Presumably, any of the phenomena described in angina patients after abrupt propranolol withdrawal ultimately, regardless of the mechanism, reflect an alteration in the myocardial oxygen supply-demand ratio. Major determinants of myocardial oxygen demand include heart rate, systolic blood pressure, contractility and left ventricular size. 40 We have measured heart rate, systolic blood pressure, left ventricular size and percent left ventricular shortening in normal subjects and heart rate and systolic blood pressure in angina patients and have shown no increases over control after propranolol withdrawal. Therefore, it is unlikely that there was increased myocardial oxygen demand during withdrawal in our subjects at rest or with exercise. Furthermore, if the catecholamine-stimulated rise in FFAs is an important influence on myocardial energetics, as suggested recently,41' 42 it does not appear to be an important mechanism for increasing myocardial oxygen consumption after abrupt propranolol withdrawal.
Recent evidence suggests that the propranolol withdrawal phenomena do not occur often. If one examines the early reports of these phenomena, one was a single institutional report3 within a larger randomized trial. Over the whole trial, propranolol withdrawal phenomena were not reported with increased frequency over control.43 Another of these reports5 involved 14 patients. In nine of these patients, increasing angina was noted even before abrupt propranolol withdrawal. Patients 
